sitafloxacin and Pneumonia--Bacterial

Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Asia, Southeastern; beta-Lactam Resistance; Carbapenems; Cross Infection; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial

We investigated the efficacy and safety of sitafloxacin (STFX) in patients with mild to moderate community-acquired pneumonia or secondary infections of chronic respiratory tract diseases. The results showed that the efficacy rate was 96.5% (111/115) in patients analyzed for efficacy. The efficacy rate by STFX administration method was 93.9% (46/49) at 50mg b.i.d., 100% (37/37) at 100 mg q.d. and 96.6% (28/29) at 100mg b.i.d. In chest X-rays, the image improvement rate in 102 patients with shadows before treatment was 94.1% (96/102). The image improvement rate by STFX administration method was 90.5% (38/42) at 50 mg b.i.d., 97.1% (33/34) at 100mg q.d. and 96.2% (25/26) at 100mg b.i.d. Side effects occurred in five out of 115 patients (4.3%). Abnormalities in hepatic function test values appeared in two patients and abnormalities in renal function test values appeared in three patients. In four cases, the abnormalities were very mild and STFX administration was continued without any treatment. In the other patient, the abnormal value rapidly returned to normal after STFX administration was discontinued. These findings indicated that STFX can be used safety in routine practice by adjusting the administration within the approved dose based on patient characteristics. Good therapeutic effects can be expected in patients with respiratory tract infections.

Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Male; Middle Aged; Pneumonia, Bacterial; Prospective Studies; Respiratory Tract Infections; Severity of Illness Index; Treatment Outcome

A novel murine model of non-typeable Haemophilus influenzae (NTHi) pneumonia was established. A plastic tube was inserted into the trachea 7 days before bacterial inoculation. Numbers of NTHi recovered from the lungs and trachea were determined for 7 days. Histologically, bronchioles and adjacent alveoli in the intubation group were filled with numerous inflammatory cells. The efficacy of sitafloxacin was compared with ciprofloxacin using the new murine pneumonia model. The data suggest that sitafloxacin displays equivalent efficacy to ciprofloxacin against H. influenzae pneumonia. This new murine NTHi pneumonia model appears useful not only for in vivo evaluation of antibiotics but also for analysis of the pathogenesis of H. influenzae pneumonia.

Topics: Animals; Anti-Bacterial Agents; Bronchioles; Ciprofloxacin; Disease Models, Animal; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Intubation, Intratracheal; Male; Mice; Pneumonia, Bacterial; Pulmonary Alveoli; Time Factors; Trachea; Treatment Outcome